A phase II, multicenter, single-arm study of pemigatinib in patients with metastatic or unresectable colorectal cancer harboring FGFR alterations
Margaret C. Wheless(Vanderbilt University Medical Center), Kristen K. Ciombor(Vanderbilt University Medical Center), L. R. Wilson(Mayo Clinic in Florida), Tyler Zemla(Mayo Clinic), Andrew B. Nixon(Duke University), Olumide B. Gbolahan(University of Colorado Cancer Center), Fang‐Shu Ou(Mayo Clinic), Blake Waechter(Mayo Clinic in Florida), John H. Strickler(Duke Medical Center), Tanios Bekaii‐Saab(WinnMed), Joleen M. Hubbard(Rutgers, The State University of New Jersey)
Cited by 3
Related Papers
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|998
Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|846
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
|JAMA Oncology|2019|472
Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years
|Journal of Oncology Practice|2017|447